A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Ibrutinib (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia; Lymphoma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 10 Apr 2017 Planned number of patients changed from 35 to 85.
- 10 Apr 2017 Status changed from active, no longer recruiting to recruiting.